Current Report Filing (8-k)
08 Dezember 2021 - 12:31PM
Edgar (US Regulatory)
false0001618835☐00016188352021-12-082021-12-080001618835us-gaap:CommonStockMember2021-12-082021-12-080001618835us-gaap:PreferredStockMember2021-12-082021-12-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 8, 2021
EVOFEM BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-36754
|
|
20-8527075
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
12400 High Bluff Drive, Suite 600, San Diego, CA 92130
(Address of principal executive offices and zip code)
(858) 550-1900
(Registrant’s telephone number, including area code)
Not applicable.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.0001 per share
|
EVFM
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
|
Series A Preferred Stock Purchase Rights, par value $0.0001 per share
|
N/A
|
The Nasdaq Stock Market LLC (Nasdaq Capital Market)
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On December 8, 2021, Evofem Biosciences, Inc. (the “Company”) issued a press release announcing that it intends to adjourn, without conducting any business, its 2021 special meeting of stockholders (the “Special Meeting”) scheduled to occur at 8:00 a.m., Pacific Standard Time, on December 8, 2021, and reconvene at 8:00 a.m., Pacific Standard Time, on December 15, 2021, to vote on the proposal described in the proxy statement filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2021. The Special Meeting will still be held at its corporate offices located at 12400 High Bluff Drive, Suite 600, San Diego, California 92130. The Company does not intend to change the record date for the Special Meeting. Only stockholders of record at the close of business on November 5, 2021 are entitled to vote at the reconvened Special Meeting.
During the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to the proposal set forth in the Company’s proxy statement. Proxies previously submitted in respect of the Special Meeting will be voted at the adjourned meeting unless properly revoked.
No changes have been made in the proposal to be voted on by stockholders at the Special Meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC remain unchanged and can be obtained free of charge at the SEC's website at www.sec.gov.
The press release is included as Exhibit 99.1 hereto, and is incorporated herein by reference.
|
|
|
|
|
|
|
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
|
|
|
|
|
Exhibit No.
|
Description
|
|
99.1
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EVOFEM BIOSCIENCES, INC.
|
|
|
|
|
|
|
Date: December 8, 2021
|
By:
|
/s/ Justin J. File
|
|
|
|
|
Justin J. File
Chief Financial Officer
|
|
Evofem Biosciences (NASDAQ:EVFM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Evofem Biosciences (NASDAQ:EVFM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
